Multigene Methylation Analysis of Conventional Renal Cell Carcinoma

Onay H., Pehlivan S., KOYUNCUOĞLU ÜLGÜN M., Kirkali Z., Ozkinay F.

UROLOGIA INTERNATIONALIS, vol.83, no.1, pp.107-112, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 83 Issue: 1
  • Publication Date: 2009
  • Doi Number: 10.1159/000224878
  • Journal Name: UROLOGIA INTERNATIONALIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.107-112
  • Keywords: Methylation, Renal cell carcinoma, PROMOTER HYPERMETHYLATION, TISSUE INHIBITOR, KIDNEY CANCER, GENE, PROFILE, TUMOR, URINE, DNA
  • Dokuz Eylül University Affiliated: Yes

Abstract

Renal cell carcinoma (RCC) is the most common malignancy of the kidney. Since RCC is curable when it is confined to the renal capsule, early diagnosis is extremely important. Promoter hypermethylation is the most common mechanism for the inactivation of the tumor suppressor genes (TSG) in the development of human cancer. This study aimed to investigate the methylation profiles of 7 TSG (RASSF1A, ECAD, TIMP3, APC, MGMT, p16 and RAR beta 2) in 3 different tissue samples (normal, premalign, malign) of patients with RCC. Twenty-one patients diagnosed with RCC were included in the study. Methylation-specific polymerase chain reaction was performed to detect the methylation patterns of the 7 TSG. High methylation rates for the genes RASSF1A (76%), p16 (80%), ECAD (42%), TIMP3 (33%) and MGMT (33%) were observed in the patients with RCC. The APC (14%) and RAR beta 2 (19%) genes showed low methylation rates. In conclusion, 5 TSG (RASSF1A, ECAD, TIMP3, MGMT and p16) showed high methylation rates in RCC patients. A methylation-based gene test including these genes may be useful in the early detection of RCC. Copyright (C) 2009 S. Karger AG, Basel